Loading
A phase 1/2 trial of ETX-19477 in ovarian cancer, prostate cancer, endometrial cancer, colorectal cancer and gastric & gastro-oesophageal junction cancer, run by 858 Therapeutics, Inc., now recruiting.
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies is a phase 1/2 interventional study registered as NCT06395519 by 858 Therapeutics, Inc., with 120 participants planned, started 2024-05-13 and due to reach its primary completion in 2026-12. Interventions recorded: ETX-19477.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Endometrial cancer, Ovarian cancer, Prostate cancer, Colorectal cancer and the tag pipeline.
Shares Endometrial cancer, Gastric & gastro-oesophageal junction cancer, Prostate cancer and the tag pipeline.
Shares Ovarian cancer, Prostate cancer and the tag pipeline.
Shares Endometrial cancer, Gastric & gastro-oesophageal junction cancer, Colorectal cancer and the tag pipeline.
Shares Ovarian cancer, Prostate cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer, Prostate cancer, Colorectal cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Colorectal cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer, Colorectal cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/